Introduction
============

Most cardiovascular diseases develop to heart failure in their advanced stages, and thus lead to death. Although various clinical means currently used for the treatment of heart failure show certain clinical effects, the most common cause of death in patients in cardiovascular medicine department is still heart failure ([@b1-etm-0-0-6114]). At present, the most commonly used and the most effective method for clinical diagnosis of heart failure is echocardiogram combined with radionuclide imaging examination, but not all hospitals and patients have access to this diagnostic method ([@b2-etm-0-0-6114]). Especially in primary hospitals, most clinical diagnoses are performed based on clinical manifestations and physicians\' experience, and error diagnoses and misdiagnoses cannot be avoided, so both false-positive and false-negative rates are high ([@b3-etm-0-0-6114]). Therefore, a diagnostic method with high positive rate and specificity is needed in clinical practices for early diagnosis and prognosis prediction of patients with heart failure ([@b4-etm-0-0-6114]).

Yu *et al* ([@b5-etm-0-0-6114]) reported that soluble growth stimulation expressed gene 2 (sST2), which was correlated with ischemic heart disease and heart failure, can be used to predict the prognosis of heart failure. However, this method is expensive and complex, so clinical popularization is difficult, especially for primary hospitals. N-terminal pro-brain natriuretic peptide (NT-proBNP) is a kind of B-type natriuretic peptide that is secreted and produced by the heart when heart failure occurs and ventricular and atrial pressure and volume loads were obviously increased ([@b5-etm-0-0-6114]). In the diagnosis of heart failure, NT-proBNP has advantages of being economic, simple and reproducible in clinical detections, and especially fits the need of a primary hospital ([@b6-etm-0-0-6114]). Matrix metalloproteinase-9 (MMP-9) is the most important cytokine that mediates myocardial remodeling and left ventricular dilatation, and plays important roles in the occurrence and development of heart failure ([@b7-etm-0-0-6114]). Yan *et al* ([@b6-etm-0-0-6114]) reported that MMP-9 could change the extracellular matrix of cardiomyocytes to promote the development of heart failure and provide important prognostic information for left ventricular remodeling in patients with heart failure. Vorovich *et al* ([@b7-etm-0-0-6114]) concluded that NT-proBNP was more clinically valuable than MMP-9 in diagnosing ventricular remodeling and predicting prognosis in patients with congestive heart failure. In this study, changes in MMP-9 and left ventricular ejection fraction (LVEF) in heart failure patients were analyzed, and NT-proBNP levels of heart failure patients with different cardiac function classifications were measured and values of risk factors of the occurrence of heart failure in evaluating the prognosis were analyzed.

Patients and methods
====================

### General data

A total of 80 heart failure patients with different cardiac functions who received treatment in Yixing People\'s Hospital from January 2016 to June 2017 were chosen. All patients met the diagnostic criteria for heart failure established by the Chinese Medical Association in 2015, and were divided into two groups (group with cardiac function in class II and below and group with cardiac function in class III and above) in accordance with the cardiac function classification of New York Heart Association (NYHA). NYHA I patients have cardiac disease but without the resulting limitations of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnoea or anginal pain. NYHA II patients have cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnoea or anginal pain. NYHA III patients have cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation, dyspnoea or anginal pain. NYHA IV patients have cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest ([@b8-etm-0-0-6114]). If any physical activity is undertaken, discomfort is increased. Before enrollment, all patients signed the informed consent or this was done by their authorized person, and this study obtained approvals from the Ethics Committee of Yixing People\'s Hospital (Yixing, China). Group with cardiac function in class II and below included 23 males and 17 females, age ranged from 45 to 75 years, with a mean age of 65.3±2.3 years old, of which 18 patients were combined with diabetes mellitus, and 15 patients were combined with hypertension; the group with cardiac function in class III and above consisted of 22 males and 18 females, and age ranged from 45 to 75 years, with an average age of 65.4±2.4 years, of which 17 patients were combined with diabetes mellitus and 15 patients were combined with hypertension. There were no statistically significant differences in sex, age, ratios of patients with diabetes mellitus and hypertension, levels of NT-proBNP, MMP-9 and LVEF between the two groups (p\>0.05).

### Methods for study and investigation

Blood biochemical test and outcome analysis were conducted. Elbow venous blood was extracted from all patients in the morning for measurement of serum NT-proBNP and MMP-9 levels. Echocardiogram examination was carried out, and correlations between NT-proBNP and MMP-9 levels in patients with different cardiac functions with LVEF level were analyzed at the same time. In terms of the analysis of risk factors, univariate analysis was first performed to process general data, such as sex, age, cardiac function, MMP-9, NT-proBNP and LVEF levels, incidence of diabetes mellitus and hypertension; then, multivariate logistic regression analyses were applied to identify independent risk factors for heart failure in patients with different cardiac functions. All researchers were trained, and a total of 160 questionnaires were sent to all patients and their attending physicians. The contents of questionnaires filled in by patients and their physicians were synthesized, analyzed and summarized.

### Assessment methods

Serum samples of all patients were derived from fasting elbow venous blood extracted from patients on the day of diagnosis. For detection of MMP-9 and NT-proBNP, ethylenediamine tetraacetic acid dipotassium anti-coagulant and Sysmex XS-500i automatic blood biochemical analyzer were used, and all samples were sent for detection within 30 min after collection. The detection was performed via bi-directional lateral flow immunosorbent assay with reagents provided by ReLIA Biotechnologies, Inc. (Shenzhen, China), and physicians with \>5 years of working experience in clinical laboratory were in strict accordance with instructions. Normal reference range of NT-proBNP was from 0 to 300. Normal reference range of MMP-9 was from 1.15 to 4.53 µg/l. Color Doppler echocardiography was performed using Sonos 5500 color Doppler ultrasound system with a frequency of 2.5--3.0 MHz. Calibration was performed automatically before measurement. Left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), LVEF (%) and data relating to cardiac ultrasound were continuously measured 3 times and averaged by the same physician who had \>5 years of working experience in ultrasonic diagnosis.

### Statistical analysis

Statistical treatment was performed via Statistical Product and Service Solutions (SPSS) 21.0. Measurement data were expressed as mean ± standard deviation (SD), and t-test was used for comparisons between the two groups, and χ^2^ test was used for intragroup comparisons. Univariate and multivariate logistic regression analyses were used to analyze relevant risk factors for heart failure in patients with different cardiac functions. Correlations between LVEF and NT-proBNP, and between LVEF and MMP-9, were analyzed using Spearman\'s rank method. P\<0.05 indicates that the difference was statistically significant.

Results
=======

### Comparison of serum NT-proBNP and MMP-9 levels in patients with different cardiac functions

The levels of serum NT-proBNP and MMP-9 in the group with cardiac function in class II and below were significantly lower than those in the group with cardiac function in class III and above (p\<0.05) ([Table I](#tI-etm-0-0-6114){ref-type="table"}).

### Comparison of levels of detected data relating to echocardiogram between the two groups

Compared with the group with cardiac function in class III and above, group with cardiac function in class II and below had obviously lower LVEDD and LVESD (p\<0.05), but higher LVEF (p\<0.05) in echocardiogram indexes ([Table II](#tII-etm-0-0-6114){ref-type="table"}).

### Analysis of correlation between NT-proBNP and LVEF levels in patients with different cardiac functions

The analysis showed that there was a negative correlation between NT-proBNP and LVEF levels \[r=−0.8517, p\<0.001 (\<0.05)\] ([Fig. 1](#f1-etm-0-0-6114){ref-type="fig"}).

### Analysis on correlation of MMP-9 level with LVEF level in patients with different cardiac functions

The analysis revealed that MMP-9 level had a negative relation with LVEF level \[r=−0.8517, p\<0.001 (\<0.05)\] ([Fig. 2](#f2-etm-0-0-6114){ref-type="fig"}).

### Univariate analysis identified relevant factors for heart failure in patients with different cardiac functions

Univariate analysis showed that cardiac function in class III and above, increased NT-proBNP, upward MMP-9 and downward LVEF were relevant risk factors of the occurrence of heart failure in patients with different cardiac functions ([Table III](#tIII-etm-0-0-6114){ref-type="table"}).

### Multivariate logistic regression analysis of the occurrence of heart failure in patients with different cardiac functions

Multivariate logistic regression analysis showed that cardiac function in class III and above, increased NT-proBNP, increased MMP-9 and decreased LVEF were independent risk factors of the occurrence of heart failure in patients with different cardiac functions ([Table IV](#tIV-etm-0-0-6114){ref-type="table"}).

Discussion
==========

Heart failure is a clinical disease with increased pre- and post-loading volumes of the heart, stasis of blood flow, and insufficient supply of blood and oxygen to main organs because of the dysfunctions of systolic and diastolic capacities and reduced pumping capability of the heart ([@b9-etm-0-0-6114]). In recent years, with changes in people\'s lifestyle and diet structure, the occurrence and development of cardiovascular diseases show an increasing trend, and onset age is also becoming younger ([@b10-etm-0-0-6114]). In addition, there are increasing number of inducements of heart failure, so the morbidity of heart failure is getting higher and higher, seriously threatening the life and health of humans ([@b11-etm-0-0-6114]). Patients with early heart failure only have complaints such as fatigue, decreased exercise tolerance and increased heart rate, which can easily be ignored ([@b12-etm-0-0-6114]), but with the prolonged course of disease and the aggravation of disease, patients may show manifestations including dyspnea on exertion, orthopnea, lung rale and even pink frothy sputum, which can reduce cardiac function and increase difficulties in treatment ([@b13-etm-0-0-6114]). Therefore, how to realize rapid and effective early diagnosis of heart failure in clinical practices and evaluate the prognosis of patients at the same time is the focus and hotspot of current studies ([@b14-etm-0-0-6114]). Previous study has shown ([@b5-etm-0-0-6114]) that plasma NT-proBNP level, which is positively correlated with the severity of heart failure, can be used as a sensitive index in assessing changes of cardiac function.

In this study, patients with different cardiac functions were divided into a group with cardiac function of class II and below and a group with cardiac function of class III and above. Comparisons of serum NT-proBNP and MMP-9 levels between the two groups revealed that the group with cardiac function in class II and below had significantly lower serum NT-proBNP and MMP-9 levels than the group with cardiac function in class III and above, suggesting that NT-proBNP and MMP-9 levels are relatively low in patients with lower class of cardiac function. At the same time, the results of the echocardiogram were compared between the two groups, and showed that LVEDD and LVESD were obviously lower in the group with cardiac function in class II and below than those in group with cardiac function in class III and above. LVEF in the group with cardiac function in class II and below was higher than that in the group with cardiac function in class III and above, indicating that patients with cardiac function in class II and below have both lower LVEDD and LVESD, but higher LVEF than patients with cardiac function in class III and above. Furthermore, analyses on correlations of NT-proBNP and MMP-9 levels with LVEF level in patients with different cardiac functions showed that NT-proBNP and MMP-9 levels were negatively related to LVEF level, which was consistent with the finding of Yan *et al* ([@b6-etm-0-0-6114]), indicating that LVEF declined with increase in NT-proBNP and MMP-9 levels, and Vorovich *et al* ([@b7-etm-0-0-6114]) suggested that NT-proBNP is superior to MMP-9 in the diagnosis and prognosis of heart failure. Moreover, analyses of factors related to the occurrence of heart failure in patients with different cardiac functions suggested that class III and above cardiac function, increased NT-proBNP and MMP-9 levels and decreased LVEF level were the relevant and independent risk factors for heart failure.

NT-proBNP, mainly synthesized by cardiomyocytes, is a biological natural hormone with the highest expression in cardiac ventricles, and is secreted mainly in the case of passive ventricular dilatation and volume overload ([@b15-etm-0-0-6114]). With the longer half-time and expression time, and higher detection sensitivity than type-B natriuretic peptide in patients with heart failure, NT-proBNP is considered to be one of the specific markers of early cardiac dysfunction, and can be used for early diagnosis of heart failure in clinical practice ([@b16-etm-0-0-6114]). When patients suffer from heart failure caused by various degrees of decompensation, the level of NT-proBNP secreted into ventricular cells is increased distinctly ([@b17-etm-0-0-6114]). High class of cardiac function reflects poor cardiac function, and is the cause of increased ventricular end-diastolic pressure, left ventricular enlargement, decreased ejection fraction ([@b18-etm-0-0-6114]), and increased NT-proBNP level. Although many studies on the relationship between the level of NT-proBNP and the development of heart failure have been reported ([@b19-etm-0-0-6114]), most patients were diagnosed based on clinical manifestations or New York Heart Function scores, and objective data were not used, especially for the LVEF evaluated by color Doppler echocardiography. In this study, correlation between NT-proBNP levels and LVEF was analyzed. Combined with the New York Heart Function assessment, we found that NT-proBNP and MMP-9 levels were elevated and LVEF levels decreased in patients with grade III cardiac function or beyond. These patients have high-risk of heart failure and prognosis is poor. Attention should be paid to these patients during clinical treatment ([@b20-etm-0-0-6114]).

In conclusion, patients with cardiac function in class II and below have relatively lower NT-proBNP and MMP-9 levels; NT-proBNP and MMP-9 levels are negatively correlated with LVEF in patients with different degrees of cardiac function; attention should be paid to patients with cardiac function in class III and above, increased NT-proBNP and MMP-9 levels and decreased LVEF in clinical practice, so as to actively prevent and treat heart failure.
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###### 

Comparison of serum NT-proBNP and MMP-9 levels in patients with different cardiac functions (x±s).

  Different cardiac functions               NT-proBNP (pg/ml)                                          MMP-9 (µg/l)
  ----------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------
  Cardiac function in class II and below    156.8±25.1^[a](#tfn1-etm-0-0-6114){ref-type="table-fn"}^   2.02±0.06^[a](#tfn1-etm-0-0-6114){ref-type="table-fn"}^
  Cardiac function in class III and above   458.9±56.3                                                 4.11±0.12
  t                                         30.996                                                     98.524
  P-value                                   \<0.001                                                    \<0.001

P\<0.05, compared with patients with heart function grade III and above. NT-proBNP, N-terminal pro-brain natriuretic peptide; MMP-9, matrix metalloproteinase-9.

###### 

Comparison of LVEDD, LVESD and LVEF in patients with different cardiac functions (x±s).

  Different cardiac functions               LVEDD (mm)                                               LVESD (mm)                                               LVEF (%)
  ----------------------------------------- -------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------
  Cardiac function in class II and below    46.8±3.6^[a](#tfn2-etm-0-0-6114){ref-type="table-fn"}^   43.5±2.9^[a](#tfn2-etm-0-0-6114){ref-type="table-fn"}^   46.5±2.9^[a](#tfn2-etm-0-0-6114){ref-type="table-fn"}^
  Cardiac function in class III and above   65.6±5.3                                                 63.3±5.0                                                 35.6±1.9
  t                                         18.558                                                   21.665                                                   19.884
  P-value                                   \<0.001                                                  \<0.001                                                  \<0.001

P\<0.05, compared with patients with heart function grade III and above. LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LVEF, left ventricular ejection fraction.

###### 

Univariate analysis on relevant factors of the occurrence of heart failure in patients with different cardiac functions.

  Relevant factors             Case   Heart failure   t or χ^2^   P-value
  ---------------------------- ------ --------------- ----------- ---------
  Sex                                                             
    Male                       45     25              0.020       0.887
    Female                     35     20                          
  Age (years)                                                     
    \>60                       55     32              2.557       0.110
    ≤60                        25     13                          
  Cardiac function                                                
    Cardiac function                                              
    in class II and below      40       7             45.741      \<0.001
    Cardiac function                                              
    in class III and above     40     38                          
  MMP-9 (µg/l)                                                    
    Normal                     35       5             44.525      \<0.001
    Upward                     45     40                          
  NT-proBNP                                                       
    Normal                     20       1             27.280      \<0.001
    Upward                     60     45                          
  LVEF (%)                                                        
    Normal                     30       3             38.769      \<0.001
    Downward                   50     42                          
  Combined with diabetes                                          
    Yes                        35     21              0.356       0.551
    No                         45     24                          
  Combined with hypertension                                      
    Yes                        30     15              0.762       0.383
    No                         50     30                          

MMP-9, matrix metalloproteinase-9; NT-proBNP, N-terminal pro-brain natriuretic peptide; LVEF, left ventricular ejection fraction.

###### 

Multivariate logistic regression analysis of patients with cardiac function in class III and above.

  Different cardiac functions               Wald test value   OR      Degree of freedom   SE      P-value
  ----------------------------------------- ----------------- ------- ------------------- ------- ---------
  Cardiac function in class III and above   5.288             0.949   0.937               2.014   0.011
  Increased NT-proBNP                       10.653            2.620   0.964               0.057   0.025
  Increased MMP-9                           6.215             1.363   0.311               0.153   0.047
  Decreased LVEF                            6.625             1.669   −0.512              0.199   0.010

OR, odds ratio; SE, standard error; NT-proBNP, N-terminal pro-brain natriuretic peptide; MMP-9, matrix metalloproteinase-9; LVEF, left ventricular ejection fraction.
